MedTrace Pharma A/S

About MedTrace Pharma A/S

MedTrace Pharma A/S sits in Other / Uncategorized, a segment Bracken sees as structurally important to the radiopharma value chain.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• Reuters Health · 2026-05-08
  Medtrace Pharma A S expands cyclotron capacity to meet Lu-177 demand
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• Endpoints News · 2026-06-27
  Medtrace Pharma A S announces Phase II readout for lead theranostic candidate
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• FierceBiotech · 2026-03-10
  Medtrace Pharma A S appoints new Chief Medical Officer ahead of pivotal trial
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• BioPharma Reporter · 2026-08-01
  Medtrace Pharma A S signs supply agreement to support late-stage trials
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Imaging Wire · 2026-05-08
  Medtrace Pharma A S closes Series C round to scale radiopharma manufacturing
  Coverage notes the company's growing footprint in the radioligand therapy space.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.